INTERVENTION 1:	Intervention	0
Placebo	Intervention	1
Placebo	Intervention	2
Placebo: matched tablet dialy	Intervention	3
INTERVENTION 2:	Intervention	4
Arzoxifene	Intervention	5
LY353381, 20 mg daily	Intervention	6
arzoxifene: one tablet daily	Intervention	7
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Current random fine needle breast aspiration (FNA) evidence of 1 of the following:	Eligibility	1
breast	UBERON:0000310	27-33
aspiration	HP:0002835	34-44
Hyperplasia with atypia	Eligibility	2
Hyperplasia without atypia but with a 10-year modified Gail risk of at least 4%	Eligibility	3
Hyperplasia without atypia but with a BRCAPRO risk of at least 25%	Eligibility	4
Hyperplasia without atypia but with a known mutation in BRCA1 or BRCA2	Eligibility	5
Hyperplasia without atypia but with a history of contralateral ductal carcinoma in situ or invasive breast cancer	Eligibility	6
history	BFO:0000182	38-45
ductal carcinoma in situ	HP:0030075,DOID:0060074	63-87
breast cancer	DOID:1612	100-113
FNA must have been taken during days 1-14 of the menstrual cycle for premenopausal women	Eligibility	7
menstrual cycle	GO:0044850	49-64
Classified as ACR class I-III on mammogram with stepwedge within past 6 months If intact uterus and/or ovaries, must have color doppler transvaginal pelvic sonogram within past 6 months showing endometrial thickening no greater than 13 mm premenopausal or no greater than 8 mm postmenopausal	Eligibility	8
uterus	UBERON:0000995	89-95
color	PATO:0000014	122-127
No ovarian cysts felt to be possibly or probably non-physiologic that have not resolved to gynecologist's satisfaction on repeat sonogram	Eligibility	9
Must agree to have or have had genetic counseling and genetic testing performed for BRCA1 and BRCA2	Eligibility	10
No active cancer (e.g., detectable disease)	Eligibility	11
active	PATO:0002354	3-9
cancer	DOID:162	10-16
disease	DOID:4,OGMS:0000031	35-42
Hormone receptor status:	Eligibility	12
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Not specified	Eligibility	13
PATIENT CHARACTERISTICS:	Eligibility	14
patient	HADO:0000008,OAE:0001817	0-7
Age:	Eligibility	15
age	PATO:0000011	0-3
18 and over	Eligibility	16
Sex:	Eligibility	17
Female	Eligibility	18
female	PATO:0000383	0-6
Menopausal status:	Eligibility	19
Any	Eligibility	20
Performance status:	Eligibility	21
Not specified	Eligibility	22
Life expectancy:	Eligibility	23
At least 12 months	Eligibility	24
Hematopoietic:	Eligibility	25
Hemoglobin greater than 10 g/dL	Eligibility	26
hemoglobin	CHEBI:35143	0-10
Granulocyte count greater than 1,000/mm^3	Eligibility	27
No deficiencies in protein C, protein S, or antithrombin III	Eligibility	28
protein c	CHEBI:82131	19-28
protein	CHEBI:36080,BAO:0000175	19-26
protein	CHEBI:36080,BAO:0000175	30-37
No activated protein C resistance	Eligibility	29
activated	BAO:0003072	3-12
protein c	CHEBI:82131	13-22
Hepatic:	Eligibility	30
Albumin greater than 3.0 g/dL	Eligibility	31
Bilirubin less than 1.5 mg/dL	Eligibility	32
AST less than 100 U/L	Eligibility	33
Alkaline phosphatase less than 200 U/L	Eligibility	34
phosphatase	GO:0016791,BAO:0000295	9-20
Renal:	Eligibility	35
Creatinine less than 1.5 mg/dL	Eligibility	36
creatinine	CHEBI:16737	0-10
Cardiovascular:	Eligibility	37
No history of deep venous thrombosis not related to trauma or pregnancy	Eligibility	38
history	BFO:0000182	3-10
deep venous thrombosis	HP:0002625	14-36
No severe coronary artery disease	Eligibility	39
severe	HP:0012828	3-9
coronary artery disease	DOID:3393	10-33
No history of prior stroke	Eligibility	40
history	BFO:0000182	3-10
stroke	HP:0001297,DOID:6713	20-26
Other:	Eligibility	41
Not pregnant or nursing	Eligibility	42
Negative pregnancy test	Eligibility	43
Fertile patients must use effective contraception during and for 3 months after study	Eligibility	44
No other active cancer	Eligibility	45
active	PATO:0002354	9-15
cancer	DOID:162	16-22
No retinal vein thrombosis	Eligibility	46
retinal	CHEBI:17898	3-10
vein	UBERON:0001638	11-15
thrombosis	DOID:0060903	16-26
No concurrent severe poorly controlled migraine	Eligibility	47
severe	HP:0012828	14-20
migraine	HP:0002076,DOID:6364	39-47
No factor V Leiden mutation carrier	Eligibility	48
carrier	CHEBI:78059,GO:0005215,BAO:0002093	28-35
PRIOR CONCURRENT THERAPY:	Eligibility	49
Biologic therapy:	Eligibility	50
At least 12 months since prior immunotherapy	Eligibility	51
Chemotherapy:	Eligibility	52
At least 3 months between completion of prior KUMC phase II difluoromethylornithine (DFMO) study and baseline aspiration	Eligibility	53
aspiration	HP:0002835	110-120
At least 12 months since prior chemotherapy	Eligibility	54
Endocrine therapy:	Eligibility	55
Must not have started or stopped hormone replacement therapy or oral contraceptives within 6 months of baseline aspiration	Eligibility	56
hormone	CHEBI:24621	33-40
aspiration	HP:0002835	112-122
Must continue all hormone replacement therapy and/or oral contraceptives that were being taken at time of baseline aspiration	Eligibility	57
hormone	CHEBI:24621	18-25
time	PATO:0000165	98-102
aspiration	HP:0002835	115-125
At least 12 months since prior tamoxifen, raloxifene, or other antihormonal therapy	Eligibility	58
tamoxifen	CHEBI:41774	31-40
raloxifene	CHEBI:8772	42-52
Radiotherapy:	Eligibility	59
radiotherapy	OAE:0000235	0-12
At least 3 months since prior radiotherapy	Eligibility	60
radiotherapy	OAE:0000235	30-42
Surgery:	Eligibility	61
surgery	OAE:0000067	0-7
At least 6 months between prior oophorectomy and baseline aspiration	Eligibility	62
aspiration	HP:0002835	58-68
Other:	Eligibility	63
At least 2 weeks since the start of other new medication that would be ingested for 1 or more months	Eligibility	64
Outcome Measurement:	Results	0
Change in Masood Score	Results	1
Change in the semi-quantitative score assigned by the designated cytopathologist.	Results	2
Range 6-24. Score represents increasing abnormality (i.e., worse appearance) Sum composite of 6 cytomorphological features, each scored as 1-4.	Results	3
range	LABO:0000114	0-5
Time frame: Baseline to 6 months	Results	4
time	PATO:0000165	0-4
Results 1:	Results	5
Arm/Group Title: Placebo	Results	6
Arm/Group Description: Placebo	Results	7
Placebo: matched tablet dialy	Results	8
Overall Number of Participants Analyzed: 84	Results	9
Mean (Standard Deviation)	Results	10
mean	BAO:0002173	0-4
standard deviation	BAO:0002176	6-24
Unit of Measure: units on a scale  -1.1         (1.9)	Results	11
Results 2:	Results	12
Arm/Group Title: Arzoxifene	Results	13
Arm/Group Description: LY353381, 20 mg daily	Results	14
arzoxifene: one tablet daily	Results	15
Overall Number of Participants Analyzed: 82	Results	16
Mean (Standard Deviation)	Results	17
mean	BAO:0002173	0-4
standard deviation	BAO:0002176	6-24
Unit of Measure: units on a scale  -0.8         (2.1)	Results	18
Adverse Events 1:	Adverse Events	0
Total: 5/101 (4.95%)	Adverse Events	1
BILATERAL CATARACTS * 0/101 (0.00%)	Adverse Events	2
bilateral	HP:0012832	0-9
APPENDICITIS * 2/101 (1.98%)	Adverse Events	3
appendicitis	DOID:8337	0-12
ISCHEMIC COLITIS * 1/101 (0.99%)	Adverse Events	4
ischemic colitis	DOID:0060181	0-16
SLIPPED DISK * 0/101 (0.00%)	Adverse Events	5
RIGHT BIMALLEOLAR ANKLE FRACTURE * 0/101 (0.00%)	Adverse Events	6
right	HP:0012834	0-5
ACUTE MYELOID LEUKEMIA * 0/101 (0.00%)	Adverse Events	7
acute myeloid leukemia	HP:0004808,DOID:9119	0-22
BREAST CANCER * 0/101 (0.00%)	Adverse Events	8
breast cancer	DOID:1612	0-13
PRIMARY DCIS IN BREAST * 0/101 (0.00%)	Adverse Events	9
breast	UBERON:0000310	16-22
OVARIAN CYST * 1/101 (0.99%)	Adverse Events	10
ovarian cyst	HP:0000138,DOID:5119	0-12
Adverse Events 2:	Adverse Events	11
Total: 9/98 (9.18%)	Adverse Events	12
BILATERAL CATARACTS * 1/98 (1.02%)	Adverse Events	13
bilateral	HP:0012832	0-9
APPENDICITIS * 0/98 (0.00%)	Adverse Events	14
appendicitis	DOID:8337	0-12
ISCHEMIC COLITIS * 0/98 (0.00%)	Adverse Events	15
ischemic colitis	DOID:0060181	0-16
SLIPPED DISK * 1/98 (1.02%)	Adverse Events	16
RIGHT BIMALLEOLAR ANKLE FRACTURE * 1/98 (1.02%)	Adverse Events	17
right	HP:0012834	0-5
ACUTE MYELOID LEUKEMIA * 1/98 (1.02%)	Adverse Events	18
acute myeloid leukemia	HP:0004808,DOID:9119	0-22
BREAST CANCER * 1/98 (1.02%)	Adverse Events	19
breast cancer	DOID:1612	0-13
PRIMARY DCIS IN BREAST * 1/98 (1.02%)	Adverse Events	20
breast	UBERON:0000310	16-22
OVARIAN CYST * 1/98 (1.02%)	Adverse Events	21
ovarian cyst	HP:0000138,DOID:5119	0-12
